116 related articles for article (PubMed ID: 24901131)
1. Adjuvant chemotherapy using gemcitabine for resected distal bile duct and ampullary cancers.
Suzuki S; Kaji S; Koike N; Harada N; Suzuki M; Hayashi T
Hepatogastroenterology; 2014; 61(130):314-8. PubMed ID: 24901131
[TBL] [Abstract][Full Text] [Related]
2. Gemcitabine-based adjuvant chemotherapy in subtypes of ampullary adenocarcinoma: international propensity score-matched cohort study.
Moekotte AL; Malleo G; van Roessel S; Bonds M; Halimi A; Zarantonello L; Napoli N; Dreyer SB; Wellner UF; Bolm L; Mavroeidis VK; Robinson S; Khalil K; Ferraro D; Mortimer MC; Harris S; Al-Sarireh B; Fusai GK; Roberts KJ; Fontana M; White SA; Soonawalla Z; Jamieson NB; Boggi U; Alseidi A; Shablak A; Wilmink JW; Primrose JN; Salvia R; Bassi C; Besselink MG; Abu Hilal M
Br J Surg; 2020 Aug; 107(9):1171-1182. PubMed ID: 32259295
[TBL] [Abstract][Full Text] [Related]
3. Survival Outcomes of Gemcitabine Plus S-1 Adjuvant Chemotherapy after Surgical Resection for Advanced Biliary Tract Cancer.
Hosoda K; Fukushima K; Shimizu A; Motoyama H; Kubota K; Notake T; Sugenoya S; Hayashi H; Yasukawa K; Kobayashi R; Soejima Y
Oncology; 2021; 99(11):703-712. PubMed ID: 34515195
[TBL] [Abstract][Full Text] [Related]
4. Prognostic factors and benefits of adjuvant therapy after pancreatoduodenectomy for ampullary adenocarcinoma: Mayo Clinic experience.
Jin Z; Hartgers ML; Sanhueza CT; Shubert CR; Alberts SR; Truty MJ; Muppa P; Nagorney DM; Smyrk TC; Hassan M; Mahipal A
Eur J Surg Oncol; 2018 May; 44(5):677-683. PubMed ID: 29506768
[TBL] [Abstract][Full Text] [Related]
5. Role of Adjuvant Multimodality Therapy After Curative-Intent Resection of Ampullary Carcinoma.
Ecker BL; Vollmer CM; Behrman SW; Allegrini V; Aversa J; Ball CG; Barrows CE; Berger AC; Cagigas MN; Christein JD; Dixon E; Fisher WE; Freedman-Weiss M; Guzman-Pruneda F; Hollis RH; House MG; Kent TS; Kowalsky SJ; Malleo G; Salem RR; Salvia R; Schmidt CR; Seykora TF; Zheng R; Zureikat AH; Dickson PV
JAMA Surg; 2019 Aug; 154(8):706-714. PubMed ID: 31141112
[TBL] [Abstract][Full Text] [Related]
6. Randomized clinical trial of adjuvant gemcitabine chemotherapy versus observation in resected bile duct cancer.
Ebata T; Hirano S; Konishi M; Uesaka K; Tsuchiya Y; Ohtsuka M; Kaneoka Y; Yamamoto M; Ambo Y; Shimizu Y; Ozawa F; Fukutomi A; Ando M; Nimura Y; Nagino M;
Br J Surg; 2018 Feb; 105(3):192-202. PubMed ID: 29405274
[TBL] [Abstract][Full Text] [Related]
7. Clinico-pathological correlates and survival outcomes in 214 resected ampullary adenocarcinomas - are outcomes different in intestinal and pancreatobiliary subtypes with adjuvant gemcitabine?
Ramaswamy A; Bhandare M; Bal M; Shrirangwar S; Kataria P; Majumdar S; Swami R; Rohila J; Chaudhari V; Mandavkar S; Chavan N; Shrikhande SV; Ostwal V
HPB (Oxford); 2020 Mar; 22(3):376-382. PubMed ID: 31405778
[TBL] [Abstract][Full Text] [Related]
8. A retrospective study of ampullary adenocarcinomas: overall survival and responsiveness to fluoropyrimidine-based chemotherapy.
Jiang ZQ; Varadhachary G; Wang X; Kopetz S; Lee JE; Wang H; Shroff R; Katz M; Wolff RA; Fleming J; Overman MJ
Ann Oncol; 2013 Sep; 24(9):2349-53. PubMed ID: 23704197
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant chemotherapy with gemcitabine and S-1 after surgical resection for advanced biliary carcinoma: outcomes and prognostic factors.
Murakami Y; Uemura K; Sudo T; Hashimoto Y; Nakashima A; Sakabe R; Kobayashi H; Kondo N; Nakagawa N; Sueda T
J Hepatobiliary Pancreat Sci; 2012 Jul; 19(4):306-13. PubMed ID: 22270151
[TBL] [Abstract][Full Text] [Related]
10. Histomorphologic and molecular phenotypes predict gemcitabine response and overall survival in adenocarcinoma of the ampulla of Vater.
Schiergens TS; Reu S; Neumann J; Renz BW; Niess H; Boeck S; Heinemann V; Bruns CJ; Jauch KW; Kleespies A
Surgery; 2015 Jul; 158(1):151-61. PubMed ID: 25819575
[TBL] [Abstract][Full Text] [Related]
11. Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial.
Malka D; Cervera P; Foulon S; Trarbach T; de la Fouchardière C; Boucher E; Fartoux L; Faivre S; Blanc JF; Viret F; Assenat E; Seufferlein T; Herrmann T; Grenier J; Hammel P; Dollinger M; André T; Hahn P; Heinemann V; Rousseau V; Ducreux M; Pignon JP; Wendum D; Rosmorduc O; Greten TF;
Lancet Oncol; 2014 Jul; 15(8):819-28. PubMed ID: 24852116
[TBL] [Abstract][Full Text] [Related]
12. A phase II trial of gemcitabine in the treatment of advanced bile duct and periampullary carcinomas.
Lin MH; Chen JS; Chen HH; Su WC
Chemotherapy; 2003 Jun; 49(3):154-8. PubMed ID: 12815209
[TBL] [Abstract][Full Text] [Related]
13. Multicenter phase II trial to investigate safety and efficacy of gemcitabine combined with cetuximab as adjuvant therapy in pancreatic cancer (ATIP).
Fensterer H; Schade-Brittinger C; Müller HH; Tebbe S; Fass J; Lindig U; Settmacher U; Schmidt WE; Märten A; Ebert MP; Kornmann M; Hofheinz R; Endlicher E; Brendel C; Barth PJ; Bartsch DK; Michl P; Gress TM;
Ann Oncol; 2013 Oct; 24(10):2576-2581. PubMed ID: 23897705
[TBL] [Abstract][Full Text] [Related]
14. [Effectiveness of adjuvant chemotherapy using gemcitabine for resected pancreatic cancer].
Suzuki S; Morishita K; Kaji S; Koike N; Harada N; Takeo Y; Hayashi T; Suzuki M; Hanyu F
Gan To Kagaku Ryoho; 2011 Jan; 38(1):65-8. PubMed ID: 21368460
[TBL] [Abstract][Full Text] [Related]
15. Role of adjuvant chemoradiation therapy in adenocarcinomas of the ampulla of vater.
Krishnan S; Rana V; Evans DB; Varadhachary G; Das P; Bhatia S; Delclos ME; Janjan NA; Wolff RA; Crane CH; Pisters PW
Int J Radiat Oncol Biol Phys; 2008 Mar; 70(3):735-43. PubMed ID: 17980502
[TBL] [Abstract][Full Text] [Related]
16. Impact of completeness of adjuvant gemcitabine, relapse pattern, and subsequent therapy on outcome of patients with resected pancreatic ductal adenocarcinoma - A pooled analysis of CONKO-001, CONKO-005, and CONKO-006 trials.
Kurreck A; Weckwerth J; Modest DP; Striefler JK; Bahra M; Bischoff S; Pelzer U; Oettle H; Kruger S; Riess H; Sinn M
Eur J Cancer; 2021 Jun; 150():250-259. PubMed ID: 33940349
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant Gemcitabine and Gemcitabine-based Chemoradiotherapy Versus Gemcitabine Alone After Pancreatic Cancer Resection: The Indiana University Experience.
Khawaja MR; Kleyman S; Yu Z; Howard T; Burns M; Nakeeb A; Loehrer PJ; Cardenes HR; Chiorean EG
Am J Clin Oncol; 2017 Feb; 40(1):42-46. PubMed ID: 25121637
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant gemcitabine alone versus gemcitabine-based chemoradiotherapy after curative resection for pancreatic cancer: a randomized EORTC-40013-22012/FFCD-9203/GERCOR phase II study.
Van Laethem JL; Hammel P; Mornex F; Azria D; Van Tienhoven G; Vergauwe P; Peeters M; Polus M; Praet M; Mauer M; Collette L; Budach V; Lutz M; Van Cutsem E; Haustermans K
J Clin Oncol; 2010 Oct; 28(29):4450-6. PubMed ID: 20837948
[TBL] [Abstract][Full Text] [Related]
19. SPARC expression in resected pancreatic cancer patients treated with gemcitabine: results from the CONKO-001 study.
Sinn M; Sinn BV; Striefler JK; Lindner JL; Stieler JM; Lohneis P; Bischoff S; Bläker H; Pelzer U; Bahra M; Dietel M; Dörken B; Oettle H; Riess H; Denkert C
Ann Oncol; 2014 May; 25(5):1025-32. PubMed ID: 24562449
[TBL] [Abstract][Full Text] [Related]
20. Membrane Localization of Human Equilibrative Nucleoside Transporter 1 in Tumor Cells May Predict Response to Adjuvant Gemcitabine in Resected Cholangiocarcinoma Patients.
Brandi G; Deserti M; Vasuri F; Farioli A; Degiovanni A; Palloni A; Frega G; Barbera MA; de Lorenzo S; Garajova I; Di Marco M; Pinna AD; Cescon M; Cucchetti A; Ercolani G; D'Errico-Grigioni A; Pantaleo MA; Biasco G; Tavolari S;
Oncologist; 2016 May; 21(5):600-7. PubMed ID: 27032872
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
